br115
mAbexperimentalTri-specific
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 30, 2024 (NCT06388902)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
CD3E activator
Epidermal growth factor receptor and ErbB2 (HER1 and HER2) inhibitor
EGFR inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes (Tri-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06388902 | Phase 1 | Apr 30, 2024 | Shanghai Bioray Laboratory Inc. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shanghai Bioray Laboratory Inc. | For profit | 1 | 1 | 1 | 2024 |
1 organizations
Page 1 / 1